is tirzepatide's price coming down Tirzepatide drop due to Medicare changes? Tirzepatide (Zepbound, Mounjaro): Weight Loss,

48% discontinuation among weight loss GLP-1 users 33% discontinuation among diabetes GLP-1 users Discontinuation of GLP-1 therapy is associated with metabolic rebound, including weight regain, rising blood pressure, and worsening glycemic control, undermining both clinical outcomes and the value of initial investment

However, there have been safety concerns and warnings about counterfeit versions and compounded semaglutide products

All regimens were associated with approximately 30% increased probability of achieving HbA1c target, 1 kg greater weight gain, and a borderline increase in the risk of severe hypoglycaemia

Treatment approaches that showed results The case report did not end with dysfunction